DexCom, Inc. (DXCM) Rating Reiterated by Oppenheimer Holdings, Inc.
DexCom, Inc. (NASDAQ:DXCM)‘s stock had its “buy” rating reaffirmed by research analysts at Oppenheimer Holdings, Inc. in a research report issued on Friday.
A number of other brokerages also recently commented on DXCM. Canaccord Genuity set a $70.00 price objective on shares of DexCom and gave the company a “buy” rating in a research report on Monday, November 14th. BMO Capital Markets initiated coverage on shares of DexCom in a research report on Friday, September 16th. They issued an “outperform” rating and a $112.00 price objective on the stock. Zacks Investment Research downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research report on Thursday, November 3rd. B. Riley raised shares of DexCom from a “neutral” rating to a “buy” rating and set a $84.00 price objective on the stock in a research report on Thursday, December 15th. Finally, BTIG Research reissued a “buy” rating on shares of DexCom in a research report on Friday. Three research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $88.67.
Shares of DexCom (NASDAQ:DXCM) traded up 30.60% on Friday, hitting $88.30. 6,286,236 shares of the company traded hands. The company’s market capitalization is $7.46 billion. DexCom has a 12 month low of $47.92 and a 12 month high of $96.38. The stock’s 50-day moving average price is $64.83 and its 200-day moving average price is $79.31.
In other news, EVP Andrew K. Balo sold 4,997 shares of the stock in a transaction dated Wednesday, October 19th. The shares were sold at an average price of $82.31, for a total value of $411,303.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Jess Roper sold 2,471 shares of the stock in a transaction dated Monday, October 24th. The shares were sold at an average price of $80.75, for a total transaction of $199,533.25. The disclosure for this sale can be found here. Company insiders own 2.80% of the company’s stock.
Several institutional investors have recently made changes to their positions in DXCM. Fort Point Capital Partners LLC bought a new position in shares of DexCom during the third quarter worth about $2,454,000. ETRADE Capital Management LLC bought a new position in shares of DexCom during the third quarter worth about $284,000. LPL Financial LLC bought a new position in shares of DexCom during the third quarter worth about $611,000. Credit Suisse AG increased its position in shares of DexCom by 93.1% in the third quarter. Credit Suisse AG now owns 103,455 shares of the medical device company’s stock worth $9,068,000 after buying an additional 49,867 shares in the last quarter. Finally, Verition Fund Management LLC bought a new position in shares of DexCom during the third quarter worth about $593,000.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.